github link
Accession IconGSE23206

NSCLC cells treated with Gefitinib

Organism Icon Homo sapiens
Sample Icon 2 Downloadable Samples
Technology Badge Icon Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)

Submitter Supplied Information

Description
About 10% of all NSCLC patients respond to gefitnib treatment and all of these patients will acquire resistance to the EGFR TKI.
PubMed ID
Publication Title
Total Samples
2
Submitter’s Institution
Authors
Source Repository
Alternate Accession IDs

Samples

Show
of 0 Total Samples
Filter
Add/Remove
Accession Code
Title
Cell line
Treatment
Processing Information
Additional Metadata
No rows found
Loading...
Some fields may be harmonized. Learn more